Computational biomedical intelligence platform for drug development
nference combines clinical data, research insights, and cloud infrastructure to accelerate drug development workflows. The tech stack reveals a security-forward engineering culture: 7 of 10 active projects focus on CI/CD hardening, container auditing, and cloud-native security defaults across AWS, Azure, and GCP. Pain points around devsecops pipeline maturity and seamless security integration suggest nference is scaling from research-oriented origins toward production-grade platform operations.
nference operates a computational biomedical platform (nSights) that synthesizes patient-level data with research knowledge to support drug development and clinical trial optimization. The company serves biotech and pharma teams at mid-market and enterprise scale. Engineering is anchored in Python, SQL, R, and Apache Spark for data processing; infrastructure runs across AWS, Azure, and GCP with Kubernetes orchestration. The product ingests HL7 and FHIR healthcare data standards and delivers clinical and biological insights back to end users. Headquarters in Cambridge positions the company within reach of both academic research networks and biotech clusters.
Python, R, SQL, Apache Spark (data), AWS/Azure/GCP (cloud), Kubernetes/Docker (infrastructure), PostgreSQL/MySQL/BigQuery (databases), HL7/FHIR (healthcare standards), and GitLab CI/CD + GitHub Actions (automation).
Seven of ten projects center on security infrastructure: CI/CD pipeline automation, container audits, cloud security integration across GCP/AWS/Azure, and secure-by-default cloud configurations. Remaining projects include customer code sandboxing and microservices architecture scaling.
Other companies in the same industry, closest in size